Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Theriva Biologics dosed the first patient in the VIRAGE2 Phase 2a trial, evaluating more frequent dosing of VCN-01 in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). The single-arm study involves six evaluable patients and aims to refine the dosing regimen for a future pivotal Phase 3 trial, with enrollment expected in H2 2026 and initial data anticipated by Q3 2027.
Key figures
- Drug Name
- VCN-01 (zabilugene almadenorepvec)
- Phase Of Trial
- Phase 2a
- Trial ids
- ["EUCT: 2026-525566-21-00","NCT07701486"]
- Evaluable patients
- 6
- Initial data readout
- Q3 2027
- Enrollment completion
- H2 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.